UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1. Name and Address of Reporting Person:
   Mahony Susan
   (Last) Mahony
   (First) Susan
   (Middle)
   C/O HORIZON THERAPEUTICS PLC
   CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON
   RD
   DUBLIN
   12,036
   0
   0
   0
   0

2. Issuer Name and Ticker or Trading Symbol
   Horizon Therapeutics Public Ltd Co [ HZNP ]

3. Date of Earliest Transaction (Month/Day/Year)
   04/30/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)
   04/30/2020

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)
2. Transaction Date (Month/Day/Year)
3. Deemed Execution Date, if any (Month/Day/Year)
4. Transaction Code (Instr. 5)
5. Amount of Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
7. Nature of Indirect Beneficial Ownership (Instr. 4)

<table>
<thead>
<tr>
<th>Security</th>
<th>Date</th>
<th>Code</th>
<th>V</th>
<th>Amount</th>
<th>Price</th>
<th>Exercisable</th>
<th>Shares</th>
<th>Beneficially Owned Following Reporting Transaction(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary</td>
<td>05/02/2020</td>
<td>M</td>
<td></td>
<td>12,036</td>
<td></td>
<td></td>
<td></td>
<td>I By Trust</td>
</tr>
<tr>
<td>Ordinary</td>
<td>05/02/2020</td>
<td>F</td>
<td></td>
<td>4,725</td>
<td>$35.62</td>
<td></td>
<td>7,311</td>
<td>I By Trust</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)
2. Conversion or Exercise Price of Derivative Security
3. Transaction Date (Month/Day/Year)
4. Deemed Execution Date, if any (Month/Day/Year)
5. Transaction Code (Instr. 5)
6. Date Exercisable and Expiration Date (Month/Day/Year)
7. Title and Amount of Derivative Security Underlying Derivative Security (Instr. 3 and 4)
8. Price of Derivative Security (Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
11. Nature of Indirect Beneficial Ownership (Instr. 4)

<table>
<thead>
<tr>
<th>Security</th>
<th>Date</th>
<th>Code</th>
<th>V</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Units</td>
<td>(1)</td>
<td>04/30/2020</td>
<td>A</td>
<td>11,098</td>
</tr>
<tr>
<td>Restricted Stock Units</td>
<td>(1)</td>
<td>05/02/2020</td>
<td>M</td>
<td>12,036</td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
2. On August 1, 2019, the reporting person was granted 12,036 restricted stock units, vesting in full on May 2, 2020.

Remarks:

A/ Miles W. McHugf,
Attorney-in-Fact
05/04/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.